{"id":"ati-1777","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"headache"},{"rate":"5-10%","effect":"nausea"},{"rate":"5-10%","effect":"fatigue"}]},"_chembl":{"chemblId":"CHEMBL5856622","moleculeType":"Small molecule","molecularWeight":"355.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, ATI-1777 reduces the activity of various cytokines and chemokines involved in inflammation and immune responses. This mechanism is thought to be beneficial in treating conditions characterized by excessive immune activity.","oneSentence":"ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:21:46.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT05432596","phase":"PHASE2","title":"Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2022-05-11","conditions":"Atopic Dermatitis","enrollment":250},{"nctId":"NCT04598269","phase":"PHASE2","title":"Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2020-09-30","conditions":"Atopic Dermatitis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ATI-1777","genericName":"ATI-1777","companyName":"Aclaris Therapeutics, Inc.","companyId":"aclaris-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes. Used for Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}